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Abstract
The inwardly rectifying potassium current (IK1) conducted through Kir2.X
channels contribute to repolarization of the cardiac action potential and to
stabilization of the resting membrane potential in cardiomyocytes. Our aim
was to investigate the effect of the recently discovered IK1 inhibitor PA-6 on
action potential repolarization and refractoriness in isolated rat hearts. Tran-
siently transfected HEK-293 cells expressing IK1 were voltage-clamped with
ramp protocols. Langendorff-perfused heart experiments were performed on
male Sprague–Dawley rats, effective refractory period, Wenckebach cycle
length, and ventricular effective refractory period were determined following
200 nmol/L PA-6 perfusion. 200 nmol/L PA-6 resulted in a significant time-
latency in drug effect on the IK1 current expressed in HEK-293 cells, giving
rise to a maximal effect at 20 min. In the Langendorff-perfused heart experi-
ments, PA-6 prolonged the ventricular action potential duration at 90% repo-
larization (from 41.8  6.5 msec to 72.6  21.1 msec, 74% compared to
baseline, P < 0.01, n = 6). In parallel, PA-6 significantly prolonged the ven-
tricular effective refractory period compared to baseline (from 34.8  4.6
msec to 58.1  14.7 msec, 67%, P < 0.01, n = 6). PA-6 increased the short-
term beat-to-beat variability and ventricular fibrillation was observed in two
of six hearts. Neither atrial ERP nor duration of atrial fibrillation was altered
following PA-6 application. The results show that pharmacological inhibition
of cardiac IK1 affects ventricular action potential repolarization and refractori-
ness and increases the risk of ventricular arrhythmia in isolated rat hearts.
Introduction
The inward rectifier potassium current (IK1) contributes
to repolarization in cardiomyocytes (Dhamoon and Jalife
2005). It is important for setting the diastolic membrane
potential (Phase 4 of the cardiac action potential, also
named resting membrane potential), and for the late
repolarization of the cardiac action potential (Phase 3)
where it constitutes a part of the repolarization reserve
currents (Ibarra et al. 1991). Consequently, changes in IK1
have significant effects on the cardiac action potential
morphology, the excitability of the heart and thereby pos-
sibly contribute to or protect against cardiac arrhythmia
(Schmitt et al. 2014).
IK1 is an inwardly rectifying potassium current prefer-
ring inward over outward conductance due to block of
the pore at depolarized membrane potentials by intracel-
lular divalent cations such as Mg2+ and Ca2+ and by
polyamines such as spermine and spermidine (Anu-
monwo and Lopatin 2010). There are four members of
this family (Kir2.1-Kir2.4), and in cardiac tissue Kir2.1 is
the predominant expressed protein. Loss of function
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mutations in KCNJ2, which encodes Kir2.1, is reported in
Andersen–Tawil syndrome (Plaster et al. 2001) and gain
of function can cause shortening of the QT-interval, both
of which increases the risk of ventricular arrhythmias
(Anumonwo and Lopatin 2010). However, the exact role
of IK1 in cardiac arrhythmias is poorly understood,
mainly due to lack of specific and efficacious IK1
modulators.
In the past, IK1 has been blocked by nonspecific com-
pounds like RP-58866 (Yang et al. 1999), MS-551 (Sen
et al. 1998), chloroquine (Rodriguez-Menchaca et al.
2008), tamoxifen (Ponce-Balbuena et al. 2009), or by
cations such as barium and cesium (Hibino et al. 2010)
(reviewed by [van der Heyden and Jespersen 2016]). The
cations were originally used for characterizing the IK1 cur-
rent and were followed by more potent and specific mole-
cules that eased the characterization of IK1 in vitro and
in vivo. However, all of the mentioned compounds affect
other targets in addition to the Kir2.x currents. More
recently a probe report showed potent block with high
selectivity toward Kir2.x using the compound, ML133
(Wu et al. 2010).
Cardiac arrhythmias associated with QTc prolongation
and U-wave alternations have been observed when pen-
tamidine is used for treatment of protozoal infections. As
U-wave deflections on the ECG (Electrocardiogram) are
associated with IK1, De Boer et al., (de Boer et al. 2010b)
investigated the mechanism and action of pentamidine
mediated IK1 block. They concluded that pentamidine
inhibits IK1 in isolated adult canine ventricular cardiomy-
ocytes and that pentamidine blocks the pore region of
Kir2.1 from the cytoplasmic side (de Boer et al. 2010b).
To obtain a more specific and potent IK1 block, Takanari
et al., examined several analogs of pentamidine, and
found PA-6 to show the highest affinity for cardiac IK1.
PA-6 blocks human Kir2.1 and 2.2 and mouse Kir 2.1, 2.2,
and 2.3 in the range 12–15 nmol/L (Takanari et al. 2013).
PA-6 thereby has a more than 10-fold lower IC50 value
for IK1 block than ML133 (180 nmol/L) (Takanari et al.
2013) (Wu et al. 2010). Furthermore, PA-6 did not signif-
icantly affect INav, ICa-L, ITo, IKr, and IKs at 200 nmol/L
(Takanari et al. 2013). In the same study, current clamp-
ing of isolated canine ventricular cardiomyocytes revealed
a drastic prolonged action potential duration and short-
term variability following PA-6 application, confirming
the prominent role of IK1 in repolarization (Takanari
et al. 2013). So far, the role of cardiac IK1 has been inves-
tigated using barium chloride, however, Ba2+ is not a
specific blocker of IK1, as it also blocks other inwardly K
+
rectifiers (Lesage et al. 1995). Furthermore, Ba2+ is toxic
and not tolerable in vivo (de Boer et al. 2010a). In order
to investigate how cardiac electrophysiology is affected by
a specific IK1 block we here use the IK1 inhibitor PA-6 to
examine the electrophysiological effects of IK1 inhibition
in Langendorff-perfused rat hearts.
Methods
Whole-cell patch-clamp recordings
Cell line preparation
IK1 currents were investigated in transiently transfected
HEK-293 cells, which were grown in Dulbecco’s modified
Eagle’s medium (DMEM; Life Technology, NY) supple-
mented with 10% fetal bovine serum (FBS; Sigma-
Aldrich, St. Louis) and 1% streptomycin (Invitrogen,
Naerum, Denmark) at 37°C in a 5% CO2 atmosphere.
Molecular cloning and transfection
Complementary DNAs encoding human Kir2.1 (GenBank
ACC. NM_000891) were subcloned into the pXOOM vec-
tor, as previously described in (Yang et al. 2010). To
reconstitute IK1 currents HEK-293 cells were transiently
transfected with 1 lg pXOOM-hKir2.1 and 0.2 lg
pcDNA3-eGFP (reporter gene). Transfections were per-
formed using Lipofectamine 2000 (Invitrogen, Naerum,
Denmark) according to the manufacturer’s instructions.
The cells were used for patch-clamp recordings 36–48 h
after transfection.
Solutions and chemicals
The following physiological extracellular solution was
used for the electrophysiological experiments, containing
(in mmol/L): NaCl 140, KCl 4, CaCl2 2, MgCl2 1, HEPES
10, D-Glucose 10 (pH 7.4 with NaOH). The pipette solu-
tion consisted of (in mmol/L) KCl 140, Na2ATP 1, EGTA
2, HEPES 10, CaCl2 0.1, MgCl2 1, D-Glucose 10 (pH 7.4
with KOH).
Electrophysiological methods
Patch-clamp recordings were performed as previously
described (Grunnet et al. 2001) (Yuan et al. 2014). HEK-
293 cells were voltage-clamped with ramp protocols.
Whole-cell currents were measured at room temperature
(20–22°C) with an EPC-9 amplifier and Pulse software
(both from HEKA Elektronik, Lambrecht, Germany).
Borosilicate glass pipettes were pulled on a DPZ-Universal
puller (Zeitz Instrumente, Munich, Germany). The pip-
ettes had a resistance of 1.5–2.5 MΩ. The series resis-
tances for whole-cell configuration were 2–5 MΩ and
were 80% compensated. At least 1.0 GΩ were achieved in
all experiments.
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Isolated Langendorff-perfused rat heart
preparations
The experiments followed the European Community Guide-
lines for the Care and Use of Experimental Animals and were
performed under License No. 2010/561-1897. All procedures
performed involving animals were in accordance with the
ethical standards of the institution at which the studies were
conducted and apply to Danish legislations. This article does
not contain any studies with human participants.
The Langendorff-perfused heart experiments were per-
formed on male Sprague–Dawley rats (Taconic A/S, Den-
mark). On the day of the experiment the rats were
weighed (BW 300–400 g) and anesthetized with a subcu-
taneous injection of fentanyl-midazolam mixture, 5 mg/
mL, dose 0.3 mL/100 g BW.
The rats were ventilated (4 mL/60 strokes/min) through
a rodent ventilator (7025 Rodent ventilator, Ugo Basile,
Italy). Tracheostomies were performed and the hearts were
excised and cannulated through a small puncture of the
aorta, near the aortic arch, and connected to the Langen-
dorff retrograde perfusion setup (Hugo Sachs Elektronik,
Harvard Apparatus GmbH, Germany). The hearts were ret-
rogradely perfused at a constant perfusion pressure of
80 mm Hg with a 37°C, pH 7.4, Krebs–Henseleit buffer
(NaCl 120.0, NaHCO3 25.0, KCl 4.0, MgSO4 0.6, NaH2PO4
0.6, CaCl2 2.5, Glucose 11.0, all in mmol/L) saturated with
95% O2 and 5% CO2. The aortic perfusion pressure was
determined with an ISOTEC transducer (Hugo Sachs Elek-
tronik, Harvard Apparatus GmbH, Germany) and the
coronary flow was measured with an ultrasonic flowmeter
(Transonic Systems INC, USA). Both were connected to an
amplifier (Hugo Sachs Elektronik, Harvard Apparatus
GmbH, Germany). The electrical activity of the rat hearts
were measured by using volume conducted electrocardio-
grams (ECGs) and by placing two epicardial monophasic
action potential (MAP) electrodes on the right ventricle.
The hearts were immersed into a temperature-controlled
and carbonated bath containing Krebs–Henseleit buffer.
Perfusion pressure, coronary flow, ECG and MAP analog
signals were sampled at a frequency of 1k/s and were con-
verted by a 16/30 data acquisition system from PowerLab
systems (ADInstruments, UK.) and monitored by using
LabChart 7 software (ADInstruments, UK.)
The hearts were left to stabilize for 30 min at intrinsic
heart rhythm. A bipolar pacing electrode was placed on
the right atrial appendage and a second pacing electrode
was positioned on the right ventricle. Epicardial pacing-
stimulation was applied using square pulses of 2 msec
durations at twice diastolic threshold at 150 basic cycle
lengths (BCL). Right atrial and right ventricular effective
refractory periods (ERPs) were measured by application
of 10 (S1) regular pulses followed by a premature extra
stimulus (S2) with the time between the S1 and the S2
stimuli increased by 2 msec increments until the refrac-
tory period was identified. Furthermore, the Wenckebach
cycle length (WCL) was determined by pacing with
decreasing cycle lengths until a 2:1 AV block appeared.
After the initial 30 min stabilization period atrial ERP
(aERP), WCL, and ventricular ERP (vERP) were determined
and the heart preparations were randomized into treatment
with either 200 nmol/L PA-6 to the drug-treated group or
equivalent amount of DMSO to the time-matched control
(named DMSO) group. The same parameters were deter-
mined every 15 min over a 90 min drug infusion period.
Compound
The pentamidine analog PA-6 (C31H32N4O2) was synthe-
sized by Syngene, Bangalore, India. The compound was dis-
solved in DMSO and the DMSO concentration in the
experiments was 0.002%. The compound was added from a
10 mmol/L stock to the Krebs–Henseleit solution used in the
experiments yielding a final concentration of 200 nmol/L.
Data analysis
Whole-cell patch-clamp data were analyzed using IGOR
Pro (WaveMetrics, Lake Oswego) and GraphPad Prism
software (GraphPad Software, San Diego). Data are pre-
sented as mean  SEM.
All Langendorff data were analyzed using Labchart 7
(ADInstruments, UK) and figures were processed in
GraphPad Prism (GraphPad Software, USA).
Data represent the mean  standard error of mean.
Two-tailed paired t-tests were used to compare baseline
with the effect of 90 min perfusion of 200 nmol/L PA-6 on
aERP, vERP, WCL, and action potential duration at 90%
repolarization (APD90). The APD90s were a mean of 40
monophasic action potentials.*P < 0.05 was considered
significant. **P < 0.01, ***P < 0.0001. The heart rate vari-
ability was evaluated using a Poincare plot. Consecutive R–
R intervals from the right ventricle were plotted as 40 n + 1
from ventricular maps. The instability of the beat-to-beat
heart rate was characterized by short-term variability (STV)
and was calculated from 40 subsequent APD90s using
(STV =
P jDnþ1  Dnj=½40
ﬃﬃ
2
p ).
Results
Time-dependent PA-6 inhibition of IK1
Because the PA-6 binding site on the Kir2.1 channel is
located at the cytosolic part of the channel, the onset of
current inhibition was slow when the drug was applied to
the extracellular solution, as also observed by De Boer
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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et al. (de Boer et al. 2010b) and Takanari et al. (Takanari
et al. 2013). To obtain a clearer picture of the time-
dependence of IK1 blockage voltage clamp experiments on
HEK-293/hKir2.1 transiently transfected cells were per-
formed (Fig. 1A). A significant time-latency in drug effect
was observed, giving rise to a maximal effect at 20 min
after application of 200 and 600 nmol/L PA-6. Applica-
tion of 66 nmol/L reached a maximal inhibitory effect of
75.8% after 35 min of drug application (Fig. 1B). To
address the relative inhibition of the inward and outward
potassium current following PA-6 inhibition current
reduction was measured at 70 mV (outward K+ cur-
rent) and 110 mV (inward K+ current) (Fig. 1C). The
K+ reversal potential was found to be approximately –
90 mV. At the three PA-6 concentrations investigated a
similar block of outward and inward IK1 was found.
Electrophysiological investigations on
Langendorff-perfused rat hearts
To investigate the electrophysiological effects of PA-6 on
the heart, in a system that allows the free concentration
of PA-6 to be precisely controlled, hearts from adult male
Sprague–Dawley rats were removed and mounted in a
Langendorff set-up. Here, retrograde perfusion through
the aorta of oxygenated saline buffer ensures the viability
of the heart for hours and using electrical stimulation it
is possible to pace and quantitate the refractoriness of
both atria and ventricle. The hearts were paced at a basic
cycle length of 150 msec to overrule intrinsic beating and
the electrical activity was measured with both monophasic
action potential (MAP) and ECG electrodes.
Due to the time latency in drug effect on IK1 PA-6 was
applied to the perfusion buffer for 90 min (Fig. 2A,B). A
time-matched control (DMSO) group was included to
investigate time stability of the experimental procedure
(Fig. 2C,D). After 90 min perfusion with 200 nmol/L PA-6
the morphology of the ventricular MAPs was drastically
changed showing a prolongation of repolarization in the
later part of the action potential, (APD90 from
41.8  6.5 msec to 72.6  21.1 msec, 74% compared to
baseline, P < 0.01, n = 6) (Figs. 2A,B and 3G). In the
DMSO group neither a change in action potential
morphology nor in action potential duration at 90% repo-
larization (APD90) was observed (Figs. 2C,D, and 3C). The
time-dependency of PA-6 effect were analyzed each 15 min.
Significant prolongation of vAPD90 was observed after
45 min (from 41.8  6.5 msec to 71.45  16.9 msec), 71%
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Figure 1. Whole-cell patch clamping of HEK-293 cells expressing IK1. (A) Representative traces. Currents were recorded in response to a
1000 msec voltage ramp protocol from 120 to +60 mV from a holding potential of 79 mV. 600 nmol/L or 200 nmol/L or 66 nmol/L of PA-
6 were added to the perfusate after getting stable whole-cell patch-clamp current. IK1 currents were following blocked with different levels by
PA-6 (gray traces). (B) Current-time relationships of IK1 during PA-6 blockage. Normalized current density with average  SEM values measured
at 118 mV (currents were elicited by the ramp protocol described above). (C) Outward and inward currents measured at 70 mV and
110 mV, respectively, 20 min after application of PA-6 at 66 nmol/L, 200 nmol/L and 600 nmol/L. 2 way ANOVA followed by Dunnett0s MC
test, error bars represent mean  SEM, *P < 0.05 was considered significant. **P < 0.01, ***P < 0.0001.
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compared to baseline, P < 0.05, n = 6) (Fig. 2E) while sig-
nificant ventricular effective refractory period (vERP) pro-
longation was found 90 min after application of 200 nmol/L
PA-6 (from 34.8  4.6 msec to 58.1  14.7 msec, 67%,
P < 0.01, n = 6) (Figs. 2E and 3F). Interestingly, the atrial
ERP was not affected by PA-6 when compared with baseline
(P = 0.12, n = 6) (Fig. 3E) and neither was the Wenckebach
cycle length (WCL), which is a measure of AV-nodal refrac-
toriness, altered by PA-6 compared to baseline (P = 0.09,
n = 6) (Fig. 3H). Neither of these parameters where chan-
ged in time-matched controls (Fig. 3A–D).
Effect of PA-6 on electrical stability
The effect of PA-6 on beating frequency, conduction and
action potential activation current (rheobase) was analyzed
prior to PA-6 and DMSO application (baseline) and after
90 min of application (Fig. 4A–D). PA-6 did not have an
effect on intrinsic heart rate (Fig. 4A), but did reduce
atria-ventricular conduction time (Fig. 4B), measured
from the start of the P-wave to the start of the QRS com-
plex on the ECG. The atrial rheobase was unaltered
(Fig. 4C), while the input current following PA-6 to elicit
action potentials in the ventricle was approximately dou-
bled (Fig. 4D). To address the effect of PA-6 on electrical
stability of the atria and ventricle the duration and fre-
quency of arrhythmia following S1–S2 stimulations were
analyzed (Fig. 4E,F). The duration of arrhythmia in the
atria was longer at 90 min compared to baseline, but no
difference was observed between the PA-6 group and the
time-matched control (DMSO) group (Fig. 4E). In con-
trast, ventricular arrhythmia lasting more than 1 sec was
observed in two hearts in the PA-6 group but in none of
the time-matched control (DMSO) hearts (Fig. 4F).
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Figure 2. Effect of PA-6 on ventricular APD90. (A) Representative MAP recordings before and after 200 nmol/L PA-6 application. (B) Summary
of vAPD90 values before and after application of 200 nmol/L PA-6 at 90 min. Individual data displayed in Figure 3G. Baseline mean
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To investigate beat-to-beat variability in the ventricles
Poincare plots were made by plotting the current APD90
value against the preceding APD90 value. In the DMSO
group the beat-to-beat variability was not changed after
application of DMSO compared to baseline, t = 0 and at
t = 90 (Fig. 5A,B), as quantified by calculating short-term
variability (STV) (Fig. 6). Application of PA-6 resulted in
a prominent change in beat-to beat variability, as illus-
trated in the monophasic action potential recordings with
indications of the individual APD90 values (Fig. 5D),
Consequently, short-term variability (STV) showed a sig-
nificant difference after application of 200 nmol/L PA-6
(P < 0.001, n = 6) (Fig. 6B).
Discussion
At this point, only few chemical entities blocking the
important cardiac Kir2.1 have a convincingly resolved
mode of action. Recently pentamidine was used as a lead
compound in the development of new potent and selec-
tive IK1 blockers (Takanari et al. 2013). 200 nmol/L PA-6
blocked more than 90% of all Kir2.x channels in a volt-
age independent manner, yielding IC50 values of 12–15
nmol/L.
This study investigates the effect of PA-6 on IK1 in
an intact heart (Langendorff) preparation. The onset of
PA-6 mediated effects showed a time-latency in the
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Figure 3. Individual effects of PA-6. (A, E) Effect of either DMSO or 200 nmol/L PA-6 on rat aERP, (B, F) vERP, (C, G) vAPD90 and (D, H) WCL.
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Langendorff-preparations, reaching a plateau after 90 min.
The slow onset of effect is probably due to PA-6 blocking
the channel pore from the cytosolic side as reported by De
Boer et al. who applied the pentamidine compound from
either the extracellular or the intracellular side of the mem-
brane using the whole-cell or inside-out patch-clamp
technique (de Boer et al. 2010b). When testing the
time-dependency of PA-6 block on HEK-293/Kir2.1 cells
by whole-cell patch clamping we also observed a profound
time-dependency of drug effect, which manifested in a
20 min latency before 200 nmol/L PA-6 produced its maxi-
mal block of the IK1 current (Fig. 1B).
Pharmacological modulation of IK1 has previously been
reported to impact the electrical stability of the heart
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Figure 4. Heart rate, conduction time, atrial and ventricular rheobase, AF and VF duration. (A) Intrinsic heart rate before and after
administration of DMSO or PA-6. DMSO or PA-6 did not significantly affect the intrinsic heart rate. (B) Atria-Ventricular conduction with
representative ECG. DMSO did not prolong the conduction time between the atrias and ventricle, but PA-6 increased the conduction time with
0.013 sec, P < 0.001. Insert, illustration of ECG following 90 min application of DMSO or PA-6. (C) Atrial rheobase, DMSO or PA-6 did not
increase the rheobase of the atria. (D) Ventricular rheobase, the ventricular rheobase was significantly increased with 173% in the ventricles
during application of PA-6, P = 0.014, n = 6. (E) S2-stimuli-induced AF. No difference between baseline and DMSO or PA-6 was observed,
n = 6, two-tailed t-test, error bars represent mean  SEM. (F) S2-induced VF duration. No significant difference was observed when comparing
baseline and DMSO in two-tailed t-test, n = 6. PA-6 the VF duration increased but was not significant, P = 0.18, two-tailed t-test, error bars
represent mean  SEM, *P < 0.05 was considered significant. **P < 0.01, ***P < 0.0001.
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(Jalife and Berenfeld 2004). Suppression of IK1 increases
APD/QT and depolarizes the diastolic potential, which
may result in both early and delayed after-depolariza-
tions, while enhancing IK1 shortens APD/QT (Dhamoon
and Jalife 2005). In agreement with this, we found that
inhibition of IK1 in the ventricles using 200 nmol/L PA-6
prolonged APD90 and increased vERP. In addition, we
found that IK1 inhibition increased the variability in the
ventricular action potential duration. This may be
arrhythmogenic due to the proarrhythmic effect of
enhanced dispersion/heterogeneity in ventricular con-
duction and repolarization (Thomsen et al. 2004;
Szentandrassy et al. 2015). Variation in repolarization
was determined by analyzing the beat-to-beat variability
in APD90. Poincare plots revealed that PA-6 significantly
increased beat-to-beat variability and STV in this isolated
heart model. The variability in action potential duration
found by Takanari et al. in canine ventricular myocytes
Takanari et al. 2013) thereby also seems to translate to
the whole beating heart. During the 90 min perfusion
two of the six PA-6 challenged hearts developed runs of
ventricular arrhythmia following S2 stimuli, suggesting
that IK1 inhibition increases the risk of ventricular
arrhythmia.
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The atrial-ventricular conduction time was also
increased by IK1 inhibition and because the Wenckebach
cycle length was not changed this indicates a conduction
slowing in the myocardium and not of the AV nodal tis-
sue. As IK1 is known to play a pivotal role in setting the
ventricular resting membrane potential (Dhamoon and
Jalife 2005) it is expected that PA-6 block induces a
depolarization of the resting membrane potential, which
will increase the fraction of inactivated cardiac sodium
channels and thus lowered tissue excitability. Further-
more, a reduced availability of sodium channels will slow
conduction due to the increased source-to-sink mismatch
(Comtois et al. 2005). The increased risk of ventricular
arrhythmia observed following loss of IK1 current (re-
viewed in [Dhamoon and Jalife 2005]) may thereby be
supported by at least three different parameters being (1)
APD90 dispersion; (2) prolonged vERP, and (3) reduced
sodium channel availability caused by a depolarized
RMP.
In the atria IK1 is believed to play a central role, but
other repolarizing potassium currents, including IK,ACh
and IK,Ca are also important in the later part of the action
potential and in setting the resting membrane potential
(Gaumond and Fried 1986; Wang et al. 2013; Skibsbye
et al. 2014; Tang et al. 2015; van der Heyden and Jes-
persen 2016). Surprisingly, application of PA-6 did not
significantly alter aERP or the duration of the S2-induced
runs of atrial arrhythmia. In rabbit and human IK1 has
been reported to be 6- to 10-fold less expressed in atria
as compared to ventricle (Giles and Imaizumi 1988;
Wang et al. 1998). A similar lower atrial IK1 in the rat
myocardium could explain the lack of PA-6 effect in rat
atria. It could also be speculated that other K+ currents,
constituting an atrial repolarization- and resting mem-
brane potential reserve, would ensure electrical stability
even when IK1 is blocked.
For many years studies of the electrophysiological func-
tion of IK1 has been limited because of the lack of selec-
tive tool compounds. However, a selective inhibitor may
not only be interesting as a tool for understanding cardiac
IK1 properties in vitro it might also have therapeutic
potential. The genesis and progression of atrial fibrillation
has been suggested to be linked to an increased IK1
(Bosch et al. 1999; Ehrlich 2008). Likewise the upregula-
tion of KCNJ2/Kir2.1 expression governed by changes in
miR-26 transcriptional levels has been linked to the pro-
motion of clinical AF (Luo et al. 2013). It can therefore
be suggested that selective pharmacological inhibition of
IK1 could serve as an antiarrhythmic principle. However,
the risk of ventricular side effects would limit clinical
application. Further, short-QT syndrome is associated
with ventricular arrhythmias and sudden cardiac death
(Pattnaik et al. 2012), and gain of function mutations in
KCNJ2 may result in arrhythmias related to Short-QT
syndrome (El Harchi et al. 2008; Hattori et al. 2012).
Selective pharmacological inhibiting of IK1 might be use-
ful in treating patients carrying such channelopathies,
although the pharmaceutical interest might be limited
due to the low number of patients diagnosed with such
phenotypes worldwide.
Study limitations
IK1 has a prominent role in controlling the resting mem-
brane potential. Therefore, we attempted to test PA-6’s
effect on rat atrial and ventricular tissue strips using
microelectrode recordings to measure action potentials
(data not shown). However, superfusion of PA-6 had no
effect on the electrophysiological properties of neither iso-
lated atrial nor ventricular tissue, possibly due to low tis-
sue penetrance of the drug as permeability is indeed
reduced in a superfused tissue strip as compared to a
coronary-perfused Langendorff heart. Such permeability
issues were previously observed for other compounds
(Skibsbye et al. 2014). Also, experiments were performed
in rat hearts which have different spatial and temporal
distribution of ionic currents compared to larger mam-
mals and humans. Hence, translatability of these findings
to larger animals or humans should be done with caution.
Exploring the ability of the PA-6 compound to influence
cardiac electrophysiology in larger animals is therefore
needed.
Conclusion
PA-6 inhibits cardiac IK1 in Langendorff-perfused rat
hearts, resulting in prolonged ventricular action potentials
Baseline DMSO
0.0
0.5
1.0
1.5
2.0
2.5
3.0
S
TV
 (m
s)
Baseline PA-6
0.0
0.5
1.0
1.5
2.0
2.5
3.0
S
TV
 (m
s)
***
A B
Figure 6. Short-term variability in the ventricle. Data from right
ventricle calculated from 40 subsequent APD90s. Two-tailed paired
t-tests were used to compare baseline with the effect of 200 nmol/
L PA-6. (A) No effect of DMSO after 90 min (n = 5, ns, P = 0.5).
(B) 200 nmol/L PA-6 increased the short-term variability (n = 6,
P = 0.0008), *P < 0.05 was considered significant. **P < 0.01,
***P < 0.0001).
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and increased refractoriness. Moreover, block of IK1 in
the rat ventricles also increases beat-to-beat variability
and STV, as well as the risk of electrical stimulated ven-
tricular arrhythmias. Atrial electrophysiology was not
altered following IK1 block. These results suggest that
blocking IK1 in rat hearts is proarrhythmic and may lead
to increased susceptibility to ventricular arrhythmia.
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